Drug Database
Back to search

Sweden· SE-20220627000144

Degarelix Accord 80 mg Pulver och vätska till injektionsvätska, lösning

A degarelix product containing degarelix, registered in Sweden by Accord Healthcare S.L.U.. The same ATC class is registered in 16 of our 19 countries.

ATC L02BX02

Checked against Swedish Medical Products Agency (Sweden) on

Informational only — not a medical device.

SOURCE REGISTER · SESwedish Medical Products Agency (Sweden)normalisedDegarelix Accord 80 mg Pulver och vät…ATCL02BX02REGISTER NO.SE-20220627000144PACKS LISTED1CHECKEDOctober 1, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about degarelixAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Degarelix is registered in 16 of 19 countries.

Countries holding a registration under ATC L02BX02 (degarelix), each read from that country’s own register.

  • This record: Sweden, from Swedish Medical Products Agency (Sweden)
  • 10 of them publish a price we can compare per daily dose
Search degarelix products by name

Degarelix · ATC L02BX02

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of degarelix costs, country by country.

Normalised to the WHO defined daily dose (2.7 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Degarelix · price per daily dose (2.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.90
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swedish Medical Products Agency (Sweden)
Active substance
Degarelix
Manufacturer
Accord Healthcare S.L.U.
Country
Sweden (SE)
ATC code
L02BX02
ATC class
Degarelix
Defined daily dose
2.7 mg, P
Reimbursed
Not published by this register
Source register
Swedish Medical Products Agency (Sweden)
Last checked
October 1, 2026

Packs & prices · 1

  • se_varunummer
    20220627000144

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

266 interactions on record for degarelix.

Graded by severity as the source publishes them — 71 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check degarelix against other medicinesHow interaction checks work

Degarelix · interactions on record

266 records

  • 71 severe
  • 192 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Degarelix in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All degarelix products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Degarelix Accord, Firmagon
  • Liechtenstein · Degarelix Accord, Firmagon
  • Norway · Degarelix Accord, Firmagon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/682d8c7c-6780-4511-bcc2-5d823b9c3362
GET /v1/drugs/682d8c7c-6780-4511-bcc2-5d823b9c3362?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "lakemedelsverket",
  "doc_types": [
    "EPAR",
    "EMA"
  ],
  "se_npl_id": "20220627000144",
  "product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20220627000144",
  "product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/degarelix-accord-epar-product-information_sv.pdf"
}
API referenceMCP serverPlans

See everything about degarelix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console